Dermatologists detect more cancers during full-body exams

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 9
Volume 18
Issue 9

Most melanomas are found during complete skin exams of patients who came to see a physician for different complaints, according to a study in the Archives of Dermatology.

Most melanomas are found during complete skin exams of patients who came to see a physician for different complaints, according to a study in the Archives of Dermatology.

Physician-detected cancers are also thinner and more likely to be only on the outer layer of skin than cancers detected by patients (Arch Dermatol 145:873-876, 2009).

Researchers at North Florida Dermatology Associates in Jacksonville found 60% of melanomas on the outer layer of the skin were detected by the dermatologist and were not among the reasons the patient came into the clinic.

Out of 126 cases of melanoma, 51 were invasive and 75 were on the outer layer of skin. The dermatologists found melanomas with a median depth of 0.33 mm vs 0.55 mm for the melanomas found by patients.

The data suggested full-body skin exams by a dermatologist would benefit individual patients and lessen the financial impact of melanoma, according to Jonathan Kantor, MD, and Deborah E. Kantor, MSN, the authors of the retrospective analysis.

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content